ResApp Health Limited advised that it has completed recruitment in its COVID-19 study in India. ResApp will use this data to develop a smartphone-based algorithm to instantly screen for COVID-19 and monitor disease progression. ResApp's Indian COVID-19 study (Clinical Trials Registry ? India: CTRI/2021/09/036581) has recruited 337 patients, including over 200 COVID-19 positive cases, across two study arms in India. Both positive and negative cases were confirmed with gold standard polymerase chain reaction (PCR) pathology testing. Outpatients and inpatients were recruited, with inpatients additionally providing cough sound samples at multiple times during their hospital stay to understand more about disease progression ResApp's US based study (clinicaltrials.gov: NCT04864535) has recently been expanded to allow recruitment from in-person COVID-19 testing clinics in addition to its existing at-home recruitment. ResApp advises that the first patient has now been recruited in the in-person testing clinic arm of the study. Recruitment in the US study is expected to complete mid-December 2021.